Dr. Gilmore Oneill, M.B., M.M.Sc., Joins Editas Medicine As...
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Dr. Gilmore Oneill, M.B., M.M.Sc., Joins Editas Medicine As President And Ceo

Pharma Tech Outlook | Monday, April 18, 2022

Editas Medicine is a prominent genome-editing firm dedicated to transforming the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of medicines for patients suffering from critical diseases all over the world.

FREMONT, CA: “I’m incredibly excited to join Editas Medicine, which has made significant strides in realizing the potential of gene editing to address previously untreatable diseases,” said Dr. ONeill. It is a great privilege to lead the Company and its talented team through its next phase of growth as we continue to transform the platform and advance clinical trials to develop and ultimately commercialize potentially life-changing medicines for people living with serious diseases."

Editas Medicine, Inc., a pioneering genome-editing firm, Declared  that Dr. Gilmore ONeill, M.B., M.M.Sc., has been named President and chief executive officer of its Board of Directors. In addition, the Company's Board of Directors will be led by James C. Mullen as Executive Chairman. These changes will take effect on June 1, 2022.

Dr. ONeill has approximately 20 years of experience in genetic medicine, neurobiology, and clinical development, contributing to Editas. Dr. ONeill also has a track record of driving and overseeing some of biotech's most successful clinical initiatives, including Amondys®, Vyondys®, Spinraza®, Plegridy®, and Tecfidera®, as well as obtaining marketing approvals for multiple drugs. He most recently worked for Sarepta Therapeutics as Executive Vice President of Research and Development and Chief Medical Officer. During his time at Sarepta, he managed the R&D leadership team to develop and direct the company's RNA and gene therapeutic portfolio's discovery, preclinical and clinical development, and worldwide regulatory strategy.

On behalf of the Board of Directors, we are delighted to appoint a leader of Gilmores caliber as the Companys CEO," said James C. Mullen, Chairman, President, and Chief Executive Officer. As more of our experimental medicines progress into and through clinical development, Gilmores significant drug development experience, proven leadership, passion for genetic medicine, and focus on patients add critical skills to Editas. I look forward to serving as Executive Chairman and partnering closely with Gilmore to ensure continuity and build on the progress Editas has made in service of those living with serious diseases and to deliver value to our shareholders."

Dr. ONeill now serves on the boards of directors of UNITY Biotechnology, Inc., a biotechnology business that develops treatments to slow, stop, or reverse ageing illnesses, and Aptinyx Inc. This biotechnology firm develops therapies to treat brain and nervous system disorders.

practice medicine.

Dr. ONeill graduated from University College Dublin with a Bachelor of Medicine and a Master of Medical Sciences from Harvard University. In the state of Massachusetts, he is licensed to practice medicine.

Weekly Brief

Read Also